NICE Rejects New Kidney Cancer Drugs
Posted on: Wednesday, 20 August 2008, 09:00 CDT
The National Institute for Health and Clinical Excellence, UK has rejected four kidney cancer treatments for use on the National Health Service on grounds that the drugs are not cost effective, according to PharmaTimes.
The draft guidance issued by the National Institute for Health and Clinical Excellence (NICE), contends that Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Wyeth's Torisel (temsirolimus) are costly for the treatment of advanced or metastatic renal cell carcinoma.
According to Peter Littlejohns, clinical and public health director at NICE, although the four drugs have the potential to extend progression-free survival by fivesix months, the treatment comes at a huge cost of GBP20,000-35,000 per patient per year. The cost per quality adjusted life year (QALY) gained of these treatments is between GBP28,500-90,600 per patient (reported by the manufacturers) and GBP71,500- 171,300 per patient, according to NICE's independent academic group. This cost factor is largely the reason behind NICE's rejection of the drugs.
However, PharmaTimes has quoted Peter Johnson, chief clinician at Cancer Research UK, as saying: "It is often difficult to get unequivocal research data in rarer cancers, such as metastatic kidney cancer, which have a small patient population."
NICE has also announced that it will look into the proposals developed by the drug manufacturers for reducing the cost of the drugs.
Source: Datamonitor
Related Articles
- Two Targeted Therapies Likely Better Than One in Patients with Aggressive Lymphoma, Mayo Clinic Researchers Say
- During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care
- Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- CPCA Celebrates Achievement in Patient, Program Success at National Health Center Week 2007
- Decreasing the Cost of Health Care, Increasing the Quality: Nation's Fourth Largest Health Insurer Completes Successful Launch of Collaborative Care System for Its Blue Cross and Blue Shield Plans in Illinois, New Mexico, Oklahoma and Texas
- Care Choices HMO Ranked in Top-Ten Health Plans Nationwide According to U.S. News & World Report/NCQA
- Avantogen and Innovate Oncology Announce Presentation of Clinical Data Demonstrating Extended Survival in Patients With Pancreatic Cancer Treated With RP101
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
- Australian Cancer Technology Reports Doubling of Mean Survival Time in Patients With Pancreatic Cancer Using RP101 With Chemotherapy Treatment
 |
 |
User Comments (0)
RSS Feeds